Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Early mortality in multiple myeloma.

Literature DB >> 25673239

Early mortality in multiple myeloma.

L J Costa¹, W I Gonsalves², S K Kumar².

Abstract

Entities: Disease

Mesh：

Year: 2015 PMID： 25673239 DOI： 10.1038/leu.2015.33

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

× No keyword cloud information.

18 in total

1. Improved long-term survival in multiple myeloma up to the age of 80 years.

Authors: S Y Kristinsson; W F Anderson; O Landgren
Journal: Leukemia Date: 2014-01-14 Impact factor: 11.528

2. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

Authors: María-Victoria Mateos; Albert Oriol; Joaquín Martínez-López; Norma Gutiérrez; Ana-Isabel Teruel; Raquel de Paz; José García-Laraña; Enrique Bengoechea; Alejandro Martín; Joaquín Díaz Mediavilla; Luis Palomera; Felipe de Arriba; Yolanda González; Jose-Mariano Hernández; Ana Sureda; José-Luis Bello; Joan Bargay; Francisco-Javier Peñalver; José-María Ribera; María-Luisa Martín-Mateos; Ramón García-Sanz; María-Teresa Cibeira; María-Luisa Martín Ramos; María-Belén Vidriales; Bruno Paiva; María-Angeles Montalbán; Juan-José Lahuerta; Joan Bladé; Jesús-Fernando San Miguel
Journal: Lancet Oncol Date: 2010-08-23 Impact factor: 41.316

3. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Authors: Philippe Moreau; Herve Avet-Loiseau; Thierry Facon; Michel Attal; Mourad Tiab; Cyrille Hulin; Chantal Doyen; Laurent Garderet; Edouard Randriamalala; Carla Araujo; Gérard Lepeu; Gerald Marit; Denis Caillot; Martine Escoffre; Bruno Lioure; Lotfi Benboubker; Brigitte Pégourié; Brigitte Kolb; Anne Marie Stoppa; Jean-Gabriel Fuzibet; Olivier Decaux; Mamoun Dib; Christian Berthou; Carine Chaleteix; Catherine Sebban; Catherine Traullé; Jean Fontan; Marc Wetterwald; Pascal Lenain; Claire Mathiot; Jean-Luc Harousseau
Journal: Blood Date: 2011-08-17 Impact factor: 22.113

4. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

Authors: Antonio Palumbo; Sara Bringhen; Tommaso Caravita; Emanuela Merla; Vincenzo Capparella; Vincenzo Callea; Clotilde Cangialosi; Mariella Grasso; Fausto Rossini; Monica Galli; Lucio Catalano; Elena Zamagni; Maria Teresa Petrucci; Valerio De Stefano; Manuela Ceccarelli; Maria Teresa Ambrosini; Ilaria Avonto; Patrizia Falco; Giovannino Ciccone; Anna Marina Liberati; Pellegrino Musto; Mario Boccadoro
Journal: Lancet Date: 2006-03-11 Impact factor: 79.321

5. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors: S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal: Lancet Oncol Date: 2009-10-21 Impact factor: 41.316

6. Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors: Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal: JAMA Date: 2004-06-09 Impact factor: 56.272

7. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Authors: Laura Rosiñol; Albert Oriol; Ana Isabel Teruel; Dolores Hernández; Javier López-Jiménez; Javier de la Rubia; Miquel Granell; Joan Besalduch; Luis Palomera; Yolanda González; María Asunción Etxebeste; Joaquín Díaz-Mediavilla; Miguel T Hernández; Felipe de Arriba; Norma C Gutiérrez; María Luisa Martín-Ramos; María Teresa Cibeira; María Victoria Mateos; Joaquín Martínez; Adrián Alegre; Juan José Lahuerta; Jesús San Miguel; Joan Bladé
Journal: Blood Date: 2012-07-12 Impact factor: 22.113

8. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Authors: Antonio Palumbo; Roman Hajek; Michel Delforge; Martin Kropff; Maria Teresa Petrucci; John Catalano; Heinz Gisslinger; Wiesław Wiktor-Jędrzejczak; Mamia Zodelava; Katja Weisel; Nicola Cascavilla; Genadi Iosava; Michele Cavo; Janusz Kloczko; Joan Bladé; Meral Beksac; Ivan Spicka; Torben Plesner; Joergen Radke; Christian Langer; Dina Ben Yehuda; Alessandro Corso; Lindsay Herbein; Zhinuan Yu; Jay Mei; Christian Jacques; Meletios A Dimopoulos
Journal: N Engl J Med Date: 2012-05-10 Impact factor: 91.245

9. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.

Authors: Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Journal: J Clin Oncol Date: 2009-12-28 Impact factor: 44.544

10. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.

Authors: Gareth J Morgan; Faith E Davies; Walter M Gregory; Kim Cocks; Sue E Bell; Alex J Szubert; Nuria Navarro-Coy; Mark T Drayson; Roger G Owen; Sylvia Feyler; A John Ashcroft; Fiona Ross; Jennifer Byrne; Huw Roddie; Claudius Rudin; Gordon Cook; Graham H Jackson; J Anthony Child
Journal: Lancet Date: 2010-12-03 Impact factor: 79.321

9 in total

Review 1. Multiple myeloma epidemiology and survival: A unique malignancy.

Authors: Dickran Kazandjian
Journal: Semin Oncol Date: 2016-11-10 Impact factor: 4.929

Review 2. Exploring Big Data in Hematological Malignancies: Challenges and Opportunities.

Authors: Gustavo F Westin; Ajoy L Dias; Ronald S Go
Journal: Curr Hematol Malig Rep Date: 2016-08 Impact factor: 3.952

3. Recognition of early mortality in multiple myeloma by a prediction matrix.

Authors: Howard Terebelo; Shankar Srinivasan; Mohit Narang; Rafat Abonour; Cristina Gasparetto; Kathleen Toomey; James W Hardin; Gail Larkins; Amani Kitali; Robert M Rifkin; Jatin J Shah
Journal: Am J Hematol Date: 2017-07-19 Impact factor: 10.047

4. Association of serum calcium levels with renal impairment and all-cause death in Chinese patients with newly diagnosed multiple myeloma: a cross-sectional, longitudinal study.

Authors: Jun Cheng; Wen Zhang; Yi Zhao; Xiayu Li; Rong Lv; Heng Li; Jianghua Chen
Journal: Nutr Metab (Lond) Date: 2021-02-11 Impact factor: 4.169

Review 5. Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment.

Authors: Gianfranco Lapietra; Francesca Fazio; Maria Teresa Petrucci
Journal: Biomolecules Date: 2022-08-19

6. Cross-Sectional and Longitudinal Associations Between the Serum G\lobulin Level, and Renal Impairment and All-Cause Deaths in Chinese Patients With Newly Diagnosed Multiple Myeloma.

Authors: Jun Cheng; Jia Sun; Yi Zhao; Xiayu Li; Yan Jiang; Rong Lv; Heng Li; Jianghua Chen
Journal: Front Oncol Date: 2022-06-08 Impact factor: 5.738